Skip to main content
Erschienen in: European Radiology 11/2018

08.05.2018 | Oncology

Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months

verfasst von: Stefania Rizzo, Francesca Botta, Sara Raimondi, Daniela Origgi, Valentina Buscarino, Anna Colarieti, Federica Tomao, Giovanni Aletti, Vanna Zanagnolo, Maria Del Grande, Nicoletta Colombo, Massimo Bellomi

Erschienen in: European Radiology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine if radiomic features, alone or combined with clinical data, are associated with residual tumour (RT) at surgery, and predict the risk of disease progression within 12 months (PD12) in ovarian cancer (OC) patients.

Methods

This retrospective study enrolled 101 patients according to the following inclusion parameters: cytoreductive surgery performed at our institution (9 May 2007–23 February 2016), assessment of BRCA mutational status, preoperative CT available. Radiomic features of the ovarian masses were extracted from 3D structures drawn on CT images. A phantom experiment was performed to assess the reproducibility of radiomic features. The final radiomic features included in the analysis (n = 516) were grouped into clusters using a hierarchical clustering procedure. The association of each cluster’s representative radiomic feature with RT and PD12 was assessed by chi-square test. Multivariate analysis was performed using logistic regression models. P values < 0.05 were considered significant.

Results

Patients with values of F2-Shape/Compactness1 below the median, of F1- GrayLevelCooccurenceMatrix25/0-1InformationMeasureCorr2 below the median and of F1-GrayLevelCooccurenceMatrix25/-333-1InverseVariance above the median showed higher risk of RT (36%, 36% and 35%, respectively, as opposed to 18%, 18% and 18%). Patients with values of F4-GrayLevelRunLengthMatrix25/-333RunPercentage above the median, of F2 shape/Max3DDiameter below the median and F1-GrayLevelCooccurenceMatrix25/45-1InverseVariance above the median showed higher risk of PD12 (22%, 24% and 23%, respectively, as opposed to 6%, 5% and 6%). At multivariate analysis F2-Shape/Max3DDiameter remained significant (odds ratio (95% CI) = 11.86 (1.41–99.88)). To predict PD12, a clinical radiomics model performed better than a base clinical model.

Conclusion

This study demonstrated significant associations between radiomic features and prognostic factors such as RT and PD12.

Key Points

• No residual tumour (RT) at surgery is the most important prognostic factor in OC.
• Radiomic features related to mass size, randomness and homogeneity were associated with RT.
• Progression of disease within 12 months (PD12) indicates worse prognosis in OC.
• A model including clinical and radiomic features performed better than only-clinical model to predict PD12.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRef Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRef
2.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRef Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRef
3.
Zurück zum Zitat Chi DS, Eisenhauer EL, Lang J et al (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559Y564CrossRef Chi DS, Eisenhauer EL, Lang J et al (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559Y564CrossRef
4.
Zurück zum Zitat Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3–10CrossRef Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3–10CrossRef
5.
Zurück zum Zitat du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234–1244CrossRef du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234–1244CrossRef
6.
Zurück zum Zitat Tan DS, Rothermundt C, Thomas K et al (2008) BRCAness syndrome in ovarian cancer: a case control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530–5536CrossRef Tan DS, Rothermundt C, Thomas K et al (2008) BRCAness syndrome in ovarian cancer: a case control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530–5536CrossRef
7.
Zurück zum Zitat Forstner R, Sala E, Kinkel K, Spencer JA (2010) ESUR guidelines: ovarian cancer staging and follow-up. European Society of Urogenital Radiology. Eur Radiol 20:2773–2780CrossRef Forstner R, Sala E, Kinkel K, Spencer JA (2010) ESUR guidelines: ovarian cancer staging and follow-up. European Society of Urogenital Radiology. Eur Radiol 20:2773–2780CrossRef
8.
Zurück zum Zitat Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577CrossRef Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577CrossRef
9.
Zurück zum Zitat Gevaert O, Xu J, Hoang CD et al (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data–methods and preliminary results. Radiology 264:387–396CrossRef Gevaert O, Xu J, Hoang CD et al (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data–methods and preliminary results. Radiology 264:387–396CrossRef
10.
Zurück zum Zitat Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272:568–576CrossRef Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272:568–576CrossRef
11.
Zurück zum Zitat Rizzo S, Petrella F, Buscarino V et al (2016) CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 26:32–42CrossRef Rizzo S, Petrella F, Buscarino V et al (2016) CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 26:32–42CrossRef
12.
Zurück zum Zitat Karlo CA, Di Paolo PL, Chaim J et al (2013) Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 270:464–471CrossRef Karlo CA, Di Paolo PL, Chaim J et al (2013) Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 270:464–471CrossRef
13.
Zurück zum Zitat Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRef Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680CrossRef
16.
Zurück zum Zitat Huang YQ, Liang CH, He L et al (2016) Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol 34:2157–2164CrossRef Huang YQ, Liang CH, He L et al (2016) Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol 34:2157–2164CrossRef
17.
Zurück zum Zitat Vargas HA, Veeraraghavan H, Micco M et al (2017) A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol 27:3991–4001CrossRef Vargas HA, Veeraraghavan H, Micco M et al (2017) A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol 27:3991–4001CrossRef
18.
Zurück zum Zitat Qiu Y, Tan M, McMeekin S et al (2016) Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol 57:1149–1155CrossRef Qiu Y, Tan M, McMeekin S et al (2016) Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol 57:1149–1155CrossRef
20.
Zurück zum Zitat Zhang L, Fried DV, Fave XJ, Hunter LA, Yang J, Court LE (2015) IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. Med Phys 42:1341–1353CrossRef Zhang L, Fried DV, Fave XJ, Hunter LA, Yang J, Court LE (2015) IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. Med Phys 42:1341–1353CrossRef
21.
Zurück zum Zitat DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 44:837–845CrossRef DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 44:837–845CrossRef
22.
Zurück zum Zitat Aletti GD, Gostout BS, Podratz KC, Cliby WA (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100:33–37CrossRef Aletti GD, Gostout BS, Podratz KC, Cliby WA (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100:33–37CrossRef
23.
Zurück zum Zitat Aletti GD, Garbi A, Messori P et al (2017) Multidisciplinary approach in the management of advanced ovarian cancer patients: a personalised approach. Results from a specialized ovarian cancer unit. Gynecol Oncol 144:468–473CrossRef Aletti GD, Garbi A, Messori P et al (2017) Multidisciplinary approach in the management of advanced ovarian cancer patients: a personalised approach. Results from a specialized ovarian cancer unit. Gynecol Oncol 144:468–473CrossRef
24.
Zurück zum Zitat Mittempergher L (2016) Genomic characterization of high-grade serous ovarian cancer: dissecting its molecular heterogeneity as a road towards effective therapeutic strategies. Curr Oncol Rep 18:44CrossRef Mittempergher L (2016) Genomic characterization of high-grade serous ovarian cancer: dissecting its molecular heterogeneity as a road towards effective therapeutic strategies. Curr Oncol Rep 18:44CrossRef
25.
Zurück zum Zitat Oza AM, Castonguay V, Tsoref D et al (2011) Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol 18:S20-7PubMed Oza AM, Castonguay V, Tsoref D et al (2011) Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol 18:S20-7PubMed
26.
Zurück zum Zitat Horvath LE, Werner T, Boucher K, Jones K (2013) The relationship between tumor size and stage in early versus advanced ovarian cancer. Med Hypotheses 80:684–687CrossRef Horvath LE, Werner T, Boucher K, Jones K (2013) The relationship between tumor size and stage in early versus advanced ovarian cancer. Med Hypotheses 80:684–687CrossRef
27.
Zurück zum Zitat Rizzo S, Calareso G, De Maria F, Zanagnolo V, Lazzari R, Cecconi A, Bellomi M (2013) Gynecologic tumors: how to communicate imaging results to the surgeon. Cancer Imaging 13:611–625CrossRef Rizzo S, Calareso G, De Maria F, Zanagnolo V, Lazzari R, Cecconi A, Bellomi M (2013) Gynecologic tumors: how to communicate imaging results to the surgeon. Cancer Imaging 13:611–625CrossRef
28.
Zurück zum Zitat Braga EA, Fridman MV, Kushlinskii NE (2017) Molecular mechanisms of ovarian carcinoma metastasis: key genes and regulatory microRNAs. Biochemistry 82:529–541PubMed Braga EA, Fridman MV, Kushlinskii NE (2017) Molecular mechanisms of ovarian carcinoma metastasis: key genes and regulatory microRNAs. Biochemistry 82:529–541PubMed
29.
Zurück zum Zitat Perneger TV (1998) What’s wrong with Bonferroni adjustments. BMJ 316:1236–1238CrossRef Perneger TV (1998) What’s wrong with Bonferroni adjustments. BMJ 316:1236–1238CrossRef
Metadaten
Titel
Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months
verfasst von
Stefania Rizzo
Francesca Botta
Sara Raimondi
Daniela Origgi
Valentina Buscarino
Anna Colarieti
Federica Tomao
Giovanni Aletti
Vanna Zanagnolo
Maria Del Grande
Nicoletta Colombo
Massimo Bellomi
Publikationsdatum
08.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 11/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5389-z

Weitere Artikel der Ausgabe 11/2018

European Radiology 11/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.